Mark Mortenson - Jun 7, 2024 Form 4 Insider Report for Clene Inc. (CLNN)

Role: Chief Science Officer
Signature: /s/ Jerry Miraglia POA
Stock symbol: CLNN
Transactions as of: Jun 7, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/10/2024, 04:17 PM
Previous filing: Jul 3, 2023
Next filing: Aug 19, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLNN	Stock Options (Right to buy)	Award	$0	+2M		$0.00	2M	Jun 7, 2024	Common Stock	2M	$0.37	Direct	F1
transaction	CLNN	Stock Options (Right to buy)	Award	$0	+800K		$0.00	800K	Jun 7, 2024	Common Stock	800K	$0.37	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on June 7, 2024 as an option for 2,000,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.
F2	This option was granted on June 7, 2024 as an option for 800,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested

Content

This option was granted on June 7, 2024 as an option for 2,000,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.

This option was granted on June 7, 2024 as an option for 800,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested